A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.

ABSTRACT:

SUBMITTER: Rosenthal A 

PROVIDER: S-EPMC4820359 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature